I-Mab has filed a patent for CD47 antibodies with low immunogenicity in humans, minimal red blood cell depletion, and hemagglutination. The claim details the specific binding domains of the antibody to human CD47. The patent also covers pharmaceutical compositions and treatment methods using these antibodies. GlobalData’s report on I-Mab gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on I-Mab, Personalized cancer vaccines was a key innovation area identified from patents. I-Mab's grant share as of January 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Cd47 antibody with low immunogenicity and rbc depletion prevention
A patent application (Publication Number: US20230399400A1) discloses claims related to an antibody or immunologically active fragment that specifically binds to human CD47 (hCD47). The antibody comprises a heavy chain variable (VH) domain with specific amino acid sequences and a light chain variable (VL) domain with distinct sequences. The claims detail the specific amino acid residues and sequences required for the antibody to bind to hCD47, including the N-terminal and C-terminal positions according to different numbering systems. Additionally, the claims cover the inclusion of an Fc domain, different types of IgG Fc domains, and various formats of the antibody or fragment, such as full-length antibodies, Fab fragments, and chimeric or humanized versions.
Furthermore, the claims describe the application of the anti-CD47 antibody in targeting hCD47 expressed on cancer cells, promoting macrophage-mediated phagocytosis of cancer cells, and preventing the interaction of hCD47 with signal-regulatory-protein a (SIRPa). The claims also specify the types of cancer cells targeted, including solid tumor and hematological cancers, and exclude binding to hCD47 on blood cells like erythrocytes. The patent application further covers methods of producing the antibody, pharmaceutical compositions containing the antibody, and methods of treating cancer in subjects using the antibody, including specific dosing regimens and administration routes. Additionally, the claims encompass the use of the antibody in combination with other treatments, such as rituximab for non-Hodgkin lymphoma, and highlight the importance of minimizing hematological toxicity in subjects undergoing treatment with the anti-CD47 antibody.
To know more about GlobalData’s detailed insights on I-Mab, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
